• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

氨苄西林-舒巴坦与头孢西丁在大鼠腹腔脓肿模型中治疗大肠杆菌感染的疗效比较

Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model.

作者信息

Rice L B, Carias L L, Shlaes D M

机构信息

Medicine Service, Department of Veterans' Affairs Medical Center, Cleveland, Ohio.

出版信息

Antimicrob Agents Chemother. 1993 Mar;37(3):610-2. doi: 10.1128/AAC.37.3.610.

DOI:10.1128/AAC.37.3.610
PMID:8460928
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC187716/
Abstract

We examined the efficacy of ampicillin-sulbactam (2:1) and cefoxitin in the treatment of infections caused by Escherichia coli strains exhibiting increasing levels of beta-lactamase-mediated resistance to ampicillin-sulbactam in the rat intra-abdominal abscess model. Cefoxitin was superior to ampicillin-sulbactam in the treatment of infections caused by all strains. Treatment with ampicillin-sulbactam resulted in a statistically significant decrease in CFU per gram of abscess in comparison with treatment with ampicillin alone for both the moderately resistant and the resistant strains, with an inverse correlation between the MIC and the absolute decrease in CFU per gram of abscess.

摘要

我们在大鼠腹腔脓肿模型中研究了氨苄西林-舒巴坦（2:1）和头孢西丁对表现出对氨苄西林-舒巴坦的β-内酰胺酶介导耐药性不断增加的大肠杆菌菌株所致感染的治疗效果。在治疗所有菌株引起的感染方面，头孢西丁优于氨苄西林-舒巴坦。对于中度耐药和耐药菌株，与单独使用氨苄西林治疗相比，用氨苄西林-舒巴坦治疗导致每克脓肿中的菌落形成单位（CFU）有统计学意义的下降，最低抑菌浓度（MIC）与每克脓肿中CFU的绝对下降之间呈负相关。

相似文献

1
Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model.氨苄西林-舒巴坦与头孢西丁在大鼠腹腔脓肿模型中治疗大肠杆菌感染的疗效比较
Antimicrob Agents Chemother. 1993 Mar;37(3):610-2. doi: 10.1128/AAC.37.3.610.
2
Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse.
Clin Infect Dis. 2000 Aug;31(2):464-71. doi: 10.1086/313971. Epub 2000 Sep 14.
3
Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections.β-内酰胺酶抑制剂组合治疗严重腹腔内感染的疗效
Ann Surg. 1993 Feb;217(2):115-21. doi: 10.1097/00000658-199302000-00004.
4
In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.抗菌药物对小鼠脆弱拟杆菌-大肠杆菌感染的体外敏感性及体内疗效
J Infect Dis. 1989 Oct;160(4):651-6. doi: 10.1093/infdis/160.4.651.
5
Antibiotic penetration of experimental intra-abdominal abscesses.实验性腹腔脓肿的抗生素渗透情况
Am Surg. 1995 Jun;61(6):521-5.
6
Comparison of cefoxitin, cefotetan and the combination of ampicillin with sulbactam in the therapy of polymicrobial infection in mice.头孢西丁、头孢替坦及氨苄西林与舒巴坦联合用药对小鼠多菌感染治疗效果的比较
J Antimicrob Chemother. 1994 Nov;34(5):791-6. doi: 10.1093/jac/34.5.791.
7
Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery.氨苄西林-舒巴坦与头孢西丁用于腹部手术高危患者预防感染的比较。
Pharmacotherapy. 1994 Nov-Dec;14(6):734-9.
8
Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.氨苄西林-舒巴坦用于治疗由产β-内酰胺酶的大肠杆菌K-1菌株引起的实验性脑膜炎。
Antimicrob Agents Chemother. 1991 Oct;35(10):2037-41. doi: 10.1128/AAC.35.10.2037.
9
Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin.
J Int Med Res. 1990;18 Suppl 4:85D-89D.
10
Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice.头孢西丁、头孢替坦和氨苄西林/舒巴坦作为小鼠多微生物感染预防药物的比较。
Clin Infect Dis. 1995 Jun;20 Suppl 2:S376-7. doi: 10.1093/clinids/20.supplement_2.s376.

引用本文的文献

1
Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.氨苄西林-舒巴坦在针对不同耐药水平大肠杆菌菌株的体外感染模型中的药效学
Antimicrob Agents Chemother. 1998 Feb;42(2):231-5. doi: 10.1128/AAC.42.2.231.
2
Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms.肺炎克雷伯菌对头孢哌酮-舒巴坦的耐药性：两种不同耐药机制共存导致耐药性增强的证据。
Antimicrob Agents Chemother. 1993 May;37(5):1061-4. doi: 10.1128/AAC.37.5.1061.
3
In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.β-内酰胺-β-内酰胺酶抑制剂组合对产TEM-26型肺炎克雷伯菌菌株的体内疗效。
Antimicrob Agents Chemother. 1994 Nov;38(11):2663-4. doi: 10.1128/AAC.38.11.2663.

本文引用的文献

1
Comparison of polyacrylamide and agarose gel thin-layer isoelectric focusing for the characterization of beta-lactamases.聚丙烯酰胺和琼脂糖凝胶薄层等电聚焦用于β-内酰胺酶表征的比较
Antimicrob Agents Chemother. 1983 Aug;24(2):186-9. doi: 10.1128/AAC.24.2.186.
2
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.肠杆菌科临床分离株对替卡西林-克拉维酸钾的耐药性：PSE-1β-内酰胺酶、高水平TEM-1和SHV-1的作用以及纸片扩散法检测中假敏感问题
Antimicrob Agents Chemother. 1988 Sep;32(9):1365-9. doi: 10.1128/AAC.32.9.1365.
3
Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins.新型质粒介导的β-内酰胺酶与第三代头孢菌素的相互作用
Rev Infect Dis. 1988 Jul-Aug;10(4):885-91. doi: 10.1093/clinids/10.4.885.
4
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.β-内酰胺酶抑制剂YTR 830、克拉维酸和舒巴坦与氨苄西林及广谱青霉素联合应用对特定产β-内酰胺酶需氧革兰氏阴性杆菌的比较活性
Antimicrob Agents Chemother. 1986 Jun;29(6):980-5. doi: 10.1128/AAC.29.6.980.
5
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.新型β-内酰胺酶抑制剂YTR 830与不同β-内酰胺类抗生素联合应用对携带已知β-内酰胺酶细菌的比较评价。
Antimicrob Agents Chemother. 1986 May;29(5):955-7. doi: 10.1128/AAC.29.5.955.
6
Amoxycillin/clavulanate resistant Escherichia coli.阿莫西林/克拉维酸耐药的大肠杆菌
Lancet. 1988 Feb 6;1(8580):304-5. doi: 10.1016/s0140-6736(88)90391-1.
7
Resistance to beta-lactam/clavulanate.对β-内酰胺/克拉维酸的耐药性。
Lancet. 1987 Dec 19;2(8573):1473. doi: 10.1016/s0140-6736(87)91180-9.
8
In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.抗菌药物对小鼠脆弱拟杆菌-大肠杆菌感染的体外敏感性及体内疗效
J Infect Dis. 1989 Oct;160(4):651-6. doi: 10.1093/infdis/160.4.651.
9
In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.抗菌剂对重症监护病房临床分离的大肠杆菌和克雷伯菌属的体外活性。
Clin Ther. 1991 Jan-Feb;13(1):25-37.
10
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.不同β-内酰胺类药物对产超广谱β-内酰胺酶肺炎克雷伯菌菌株在大鼠腹腔脓肿模型中的疗效
Antimicrob Agents Chemother. 1991 Jun;35(6):1243-4. doi: 10.1128/AAC.35.6.1243.